移植片対宿主病(Graft Versus Host Disease (GVHD))：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Graft Versus Host Disease (GVHD) Overview 10
Therapeutics Development 11
Pipeline Products for Graft Versus Host Disease (GVHD) – Overview 11
Pipeline Products for Graft Versus Host Disease (GVHD) – Comparative Analysis 12
Graft Versus Host Disease (GVHD) – Therapeutics under Development by Companies 13
Graft Versus Host Disease (GVHD) – Therapeutics under Investigation by Universities/Institutes 18
Graft Versus Host Disease (GVHD) – Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Graft Versus Host Disease (GVHD) – Products under Development by Companies 23
Graft Versus Host Disease (GVHD) – Products under Investigation by Universities/Institutes 27
Graft Versus Host Disease (GVHD) – Companies Involved in Therapeutics Development 28
AbGenomics International, Inc. 28
Adienne Pharma & Biotech 29
Alder Biopharmaceuticals Inc. 30
Alexion Pharmaceuticals, Inc. 31
Apceth GmbH & Co. KG 32
Athersys, Inc. 33
Bellicum Pharmaceuticals, Inc. 34
Biogen Idec Inc. 35
Dr. Falk Pharma GmbH 36
Enlivex Therapeutics Ltd 37
Escape Therapeutics, Inc. 38
F. Hoffmann-La Roche Ltd. 39
Generon (Shanghai) Corporation Ltd. 40
Idera Pharmaceuticals, Inc. 41
ImmuNext, Inc. 42
Immunomedics, Inc. 43
Jazz Pharmaceuticals plc 44
Kadmon Corporation, LLC 45
Kamada Ltd. 46
Kymab Limited 47
Lycera Corp. 48
Mesoblast Limited 49
Millennium Pharmaceuticals, Inc. 50
MSM Protein Technologies, Inc. 51
Neopharm Ltd. 52
NeoStem, Inc. 53
Novartis AG 54
Omni Bio Pharmaceutical Inc. 55
Pharmacyclics, Inc. 56
Pharmicell Co., Ltd. 57
Pluristem Therapeutics Inc. 58
R-Tech Ueno, Ltd. 59
REGiMMUNE Corporation 60
Rigel Pharmaceuticals, Inc. 61
Sarepta Therapeutics, Inc. 62
Seattle Genetics, Inc. 63
Sigmoid Pharma Limited 64
Soligenix, Inc. 65
Spherium Biomed S.L. 66
Targazyme, Inc. 67
Therapix Biosciences Ltd 68
Tobira Therapeutics, Inc. 69
Xenikos B.V. 70
Graft Versus Host Disease (GVHD) – Therapeutics Assessment 71
Assessment by Monotherapy Products 71
Assessment by Combination Products 72
Assessment by Target 73
Assessment by Mechanism of Action 76
Assessment by Route of Administration 79
Assessment by Molecule Type 81
Drug Profiles 83
AbGn-168H – Drug Profile 83
aldesleukin – Drug Profile 85
Alecmestencel-L – Drug Profile 87
Alpha-1 Antitrypsin – Drug Profile 88
alpha-1 proteinase inhibitor (human) – Drug Profile 89
ALXN-1007 – Drug Profile 91
anti-thymocyte globulin (rabbit) – Drug Profile 92
Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD – Drug Profile 94
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease – Drug Profile 95
ApoCell – Drug Profile 96
beclomethasone dipropionate – Drug Profile 97
begelomab – Drug Profile 99
bortezomib – Drug Profile 100
BPX-501 – Drug Profile 105
brentuximab vedotin – Drug Profile 107
budesonide – Drug Profile 112
Bz-423 – Drug Profile 115
cannabidiol – Drug Profile 116
Cell Therapy for Autoimmune Diseases and GVHD – Drug Profile 117
Cell Therapy for CNS, Respiratory, Immunology and Metabolic Disorders – Drug Profile 119
Cell Therapy for Graft Versus Host Disease – Drug Profile 120
Cell Therapy for Graft Versus Host Disease – Drug Profile 121
Cell Therapy for Graft Versus Host Disease – Drug Profile 122
Cell Therapy for Graft versus Host Disease – Drug Profile 123
Cell Therapy for Graft-Versus Host Disease – Drug Profile 124
Cell Therapy for GVHD – Drug Profile 125
cenicriviroc mesylate – Drug Profile 126
Cerecellgram for Graft Versus Host Disease – Drug Profile 128
clazakizumab – Drug Profile 129
Coversin – Drug Profile 131
cyclosporine IR + cyclosporine CR – Drug Profile 132
defibrotide – Drug Profile 133
Drugs for Acute and Chronic GVHD – Drug Profile 136
Drugs for Graft Versus Host Disease – Drug Profile 137
erismodegib – Drug Profile 138
F-652 – Drug Profile 141
Fc-Alpha-1 Antitrypsin – Drug Profile 142
FcAAT-2 – Drug Profile 143
FcAAT-3 – Drug Profile 144
Ha-7 – Drug Profile 145
ibrutinib – Drug Profile 146
ImmuneSafe – Drug Profile 152
ImmuStem – Drug Profile 153
IMO-8400 – Drug Profile 154
inolimomab – Drug Profile 156
IT-603 – Drug Profile 157
IT-901 – Drug Profile 158
KD-025 – Drug Profile 159
KY-1005 – Drug Profile 161
milatuzumab – Drug Profile 162
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases – Drug Profile 164
MSM-707 – Drug Profile 166
MultiStem – Drug Profile 167
natalizumab – Drug Profile 170
Oligonucleotide to Inhibit NFAT1 for GVHD – Drug Profile 172
panobinostat – Drug Profile 173
PLX-RAD – Drug Profile 179
Protein to Activate TLR5 for Infectious Disease and GVHD – Drug Profile 182
Recombinant HIV Gp120 Protein for GvHD And Autoimmune Disorders – Drug Profile 183
Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease – Drug Profile 184
remestemcel-L – Drug Profile 185
RGI-2001 – Drug Profile 188
RO-2959 – Drug Profile 190
Small Molecule for Graft Versus Host Disease, Hemophagocytic Lymphohistiocytosis and Autoimmune Disorders – Drug Profile 191
Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorder – Drug Profile 192
Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia – Drug Profile 193
Small Molecules to Inhibit SHIP1 for Oncology and Immunology – Drug Profile 194
SP-12008 – Drug Profile 195
T-Guard – Drug Profile 196
TZ-101 – Drug Profile 198
Graft Versus Host Disease (GVHD) – Recent Pipeline Updates 200
Graft Versus Host Disease (GVHD) – Dormant Projects 283
Graft Versus Host Disease (GVHD) – Discontinued Products 287
Graft Versus Host Disease (GVHD) – Product Development Milestones 288
Featured News & Press Releases 288
Appendix 296
Methodology 296
Coverage 296
Secondary Research 296
Primary Research 296
Expert Panel Validation 296
Contact Us 296
Disclaimer 297